Cantor Fitzgerald’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Cantor Fitzgerald’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,000	Closed	-$70K	–	817
2022 Q4	$70K	Sell	12,000 -30,100	-71%	-$158K	﹤0.01%	614
2022 Q3	$282K	Buy	+42,100	New	+$255K	0.01%	574

Cantor Fitzgerald's CNCE Position: Q1 2023 in Review

Cantor Fitzgerald sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 12,000 shares — an estimated $70K sold.

Cantor Fitzgerald first reported a position in CNCE in Q3 2022 and held it in 2 quarters. The position peaked at $282K in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Cantor Fitzgerald reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Cantor Fitzgerald sold 12,000 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $70K.
Cantor Fitzgerald first reported a position in Concert Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
Cantor Fitzgerald's Concert Pharmaceuticals, Inc. position peaked at $282K in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Cantor Fitzgerald's 13F filing for Q1 2023, filed 15 May 2023.